Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 21
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

MacroH2As regulate enhancer-promoter contacts affecting enhancer activity and sensitivity to inflammatory cytokines

  • Corujo, David
  • Malinverni, Roberto
  • Carrillo-Reixach, Juan
  • Meers, Oliver
  • Garcia-Jaraquemada, Arce
  • Le Pannérer, Marguerite-Marie, 1990-
  • Valero, Vanesa
  • Pérez, Ainhoa
  • Del Río-Álvarez, Álvaro
  • Royo, Laura
  • Pérez-González, Beatriz
  • Raurell Vila, Helena
  • Acemel, Rafael D.
  • Santos-Pereira, José M.
  • Gómez Skarmeta, José Luis
  • Pasquali, Lorenzo
  • Manyé, Josep
  • Armengol, Carolina
  • Buschbeck, Marcus
MacroH2A histone variants have a function in gene regulation that is poorly understood at the molecular level. We report that macroH2A1.2 and macroH2A2 modulate the transcriptional ground state of cancer cells and how they respond to inflammatory cytokines. Removal of macroH2A1.2 and macroH2A2 in hepatoblastoma cells affects the contact frequency of promoters and distal enhancers coinciding with changes in enhancer activity or preceding them in response to the cytokine tumor necrosis factor alpha. Although macroH2As regulate genes in both directions, they globally facilitate the nuclear factor κB (NF-κB)-mediated response. In contrast, macroH2As suppress the response to the pro-inflammatory cytokine interferon gamma. MacroH2A2 has a stronger contribution to gene repression than macroH2A1.2. Taken together, our results suggest that macroH2As have a role in regulating the response of cancer cells to inflammatory signals on the level of chromatin structure. This is likely relevant for the interaction of cancer cells with immune cells of their microenvironment., This research project was supported by the national grants RTI2018-094005-B-I00 and BFU2015-66559-P from FEDER / Ministerio de Ciencia e Innovación - Agencia Estatal de Investigación (to M.B.); PI09/00751 , PI10/02082 , and PI13/02340 from the Instituto de Salud Carlos III (to C.A.); the MECD fellowship FPU14/06542 (to D.C.); AGAUR 2019 FI_B01024 and 2022 FI_B00528 fellowships (to J.C.-R. and A.D.R.-A., respectively); and predoctoral fellowships BES-2016-077251 (to M.-M.L.P.) and PRE2019-088529 (to O.M.). Research in the M.B. lab is further supported by the following grants: the Marie Skłodowska Curie Training network “ INTERCEPT-MDS ” H2020-MSCA-ITN-2020-953407 (to M.B.); MINECO-ISCIII PIE16/00011 (to M.B.); the Deutsche José Carreras Leukämie Stiftung DJCLS 14R/2018 (to M.B.); AGAUR 2017-SGR-305 (to M.B.); and Fundació La Marató de TV3 257/C/2019 (to M.B.). C.A.’s research has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement nos. 668596 ( ChiLTERN ) and 826121 ( iPC ) as well as from CIBERehd ( CB06/04/0033 ) and AGAUR ( 2017-SGR-490 ). C.A. was supported by Ramón y Cajal ( RYC-2010-07249 ) of the Ministry of Science and Innovation of Spain. Research at the IJC is supported by the “ La Caixa” Foundation , the Fundació Internacional Josep Carreras , Celgene Spain , and the CERCA Programme / Generalitat de Catalunya.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Analyzing sex imbalance in EGA and dbGaP biological databases: Recommendations for better practices

  • Ruiz-Serra, Victoria
  • Buslón, Nataly
  • Philippe, Olivier
  • Saby, Diego
  • Morales, María
  • Pontes, Camila
  • Muñoz Andirkó, Alejandro
  • Holliday, Gemma L.
  • Jene, Aina
  • Moldes, Mauricio
  • Rambla de Argila, Jordi
  • Valencia, Alfonso
  • Rementeria, María José
  • Cortés, Atia
  • Cirillo, Davide
Precision medicine aims at tailoring treatments to individual patient's characteristics. In this regard, recognizing the significance of sex and gender becomes indispensable for meeting the distinct healthcare needs of diverse populations. To this end, continuing a trend of improving data quality observed since 2014, the European Genome-phenome Archive (EGA) established a policy in 2018 that mandates data providers to declare the sex of donor samples, aiming to enhance data accuracy and prevent imbalance in sex classification. We analyzed sex classification imbalance in human data from EGA and the U.S. counterpart, the database of genotypes and phenotypes (dbGaP). Our findings show a significant decrease in samples classified as unknown in EGA, potentially promoting better sex reporting during data collection. Based on our findings, we raise awareness of sample imbalance problems and provide a list of recommendations for enhancing biomedical research practices., The work has been supported by Bioinfo4Women through the project Excelencia Severo Ochoa (ref. CEX2021-001148-S) and the European Commission's Horizon 2020 Program, H2020-SC1-DTH-2018-2020, “iPC - individualizedPaediatricCure” (GA 826121). This work was conceptualized and prototyped during the BioHackathon Europe, organized and funded by the ELIXIR Hub in November 2021 in Barcelona. We thank the organizers for an opportunity to participate in such a productive and collaborative event. The authors would like to acknowledge the initiative Bioinfo4Women, Laura Rodríguez Navas (Spanish National Bioinformatics Institute, INB/ELIXIR-ES and Barcelona Supercomputing Center, BSC), Eva Alloza (Spanish National Bioinformatics Institute, INB/ELIXIR-ES and Barcelona Supercomputing Center, BSC), Francisco Garcia-Garcia (Prince Felipe Research Center, CIPF), Babita Singh (Center for Genomic Regulation, CRG), Ben Busby (DNANexus), and Michael Feolo (dbGaP) and the NCBI dbGaP support team. C.P. is supported by the fellowship Juan de La Cierva - Formación from the Spanish Ministry of Education and Science (ref. FJC2021-046655-I).
Repisalud
Publicación Artículo científico (JournalArticle)

Systematic multi-omics cell line profiling uncovers principles of Ewing sarcoma fusion oncogene-mediated gene regulation

  • Orth, Martin F
  • Surdez, Didier
  • Faehling, Tobias
  • Ehlers, Anna C
  • Marchetto, Aruna
  • Grossetête, Sandrine
  • Volckmann, Richard
  • Zwijnenburg, Danny A
  • Gerke, Julia S
  • Zaidi, Sakina
  • Alonso, Javier
  • Sastre, Ana
  • Baulande, Sylvain
  • Sill, Martin
  • Cidre-Aranaz, Florencia
  • Ohmura, Shunya
  • Kirchner, Thomas
  • Hauck, Stefanie M
  • Reischl, Eva
  • Gymrek, Melissa
  • Pfister, Stefan M
  • Strauch, Konstantin
  • Koster, Jan
  • Delattre, Olivier
  • Grünewald, Thomas G P
Ewing sarcoma (EwS) is characterized by EWSR1-ETS fusion transcription factors converting polymorphic GGAA microsatellites (mSats) into potent neo-enhancers. Although the paucity of additional mutations makes EwS a genuine model to study principles of cooperation between dominant fusion oncogenes and neo-enhancers, this is impeded by the limited number of well-characterized models. Here we present the Ewing Sarcoma Cell Line Atlas (ESCLA), comprising whole-genome, DNA methylation, transcriptome, proteome, and chromatin immunoprecipitation sequencing (ChIP-seq) data of 18 cell lines with inducible EWSR1-ETS knockdown. The ESCLA shows hundreds of EWSR1-ETS-targets, the nature of EWSR1-ETS-preferred GGAA mSats, and putative indirect modes of EWSR1-ETS-mediated gene regulation, converging in the duality of a specific but plastic EwS signature. We identify heterogeneously regulated EWSR1-ETS-targets as potential prognostic EwS biomarkers. Our freely available ESCLA (http://r2platform.com/escla/) is a rich resource for EwS research and highlights the power of comprehensive datasets to unravel principles of heterogeneous gene regulation by chimeric transcription factors.
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

DECONbench: a benchmarking platform dedicated to deconvolution methods for tumor heterogeneity quantification

  • Decamps, Clémentine
  • Arnaud, Alexis
  • Petitprez, Florent
  • Ayadi, Mira
  • Baurès, Aurélia
  • Armenoult, Lucile
  • Escalera Guerrero, Sergio
  • Guyon, Isabelle
  • Nicolle, Rémy
  • Tomasini, Richard
  • Reyniès, Aurélien de
  • Cros, Jérôme
  • Blum, Yuna
  • Richard, Magali
Quantifcation of tumor heterogeneity is essential to better understand cancer progression and to adapt therapeutic treatments to patient specifcities. Bioinformatic tools to assess the diferent cell populations from single-omic datasets as bulk transcriptome or methylome samples have been recently developed, including reference-based and reference-free methods. Improved methods using multi-omic datasets are yet to be developed in the future and the community would need systematic tools to perform a comparative evaluation of these algorithms on controlled data.
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

Epigenetic footprint enables molecular risk stratification of hepatoblastoma with clinical implications

  • Carrillo Reixach, Juan
  • Torrens, Laura
  • Simon Coma, Marina
  • Royo, Laura
  • Domingo Sàbat, Montserrat
  • Abril Fornaguera, Jordi
  • Akers, Nicholas
  • Sala, Margarita
  • Ragull Tisner, Sònia
  • Arnal, Magdalena
  • Villalmanzo, Núria
  • Cairo, Stefano
  • Villanueva Garatachea, Alberto
  • Kappler, Roland
  • Garrido, Marta
  • Guerra, Laura
  • Sabado, Constantino
  • Guillén, Gabriela
  • Mallo, Mar
  • Piñeyro, David
  • Vázquez Vitali, María
  • Kuchuk, Olga
  • Mateos, María Elena
  • Ramírez, Gema
  • López Santamaría, Manuel
  • Mozo, Yasmina
  • Soriano, Aroa
  • Grotzer, Michael
  • Branchereau, Sophie
  • García de Andoin, Nagore
  • López Ibor, Blanca
  • López Almaraz, Ricardo
  • Salinas, José Antonio
  • Torres, Bárbara
  • Hernández, Francisco
  • Uriz, José Javier
  • Fabre, Monique
  • Blanco, Julià
  • Paris, Claudia
  • Bajciová, Viera
  • Laureys, Geneviève
  • Masnou, Helena
  • Clos, Ariadna
  • Belendez, Cristina
  • Guettier, Catherine
  • Sumoy, Lauro
  • Planas, Ramón
  • Jordà Ramos, Mireia
  • Nonell, Lara
  • Czauderna, Piotr
  • Morland, Bruce
  • Sia, Daniela
  • Losic, Bojan
  • Buendia, Marie Annick
  • Sarrias Fornés, Maria Rosa
  • Llovet i Bayer, Josep Maria
  • Armengol, Carolina
Background & Aims: Hepatoblastoma (HB) is a rare disease. Nevertheless, it is the predominant pediatric liver cancer, with limited therapeutic options for patients with aggressive tumors. Herein, we aimed to uncover the mechanisms of HB pathobiology and to identify new biomarkers and therapeutic targets in a move towards precision medicine for patients with advanced HB. Methods: We performed a comprehensive genomic, transcriptomic and epigenomic characterization of 159 clinically annotated samples from 113 patients with HB, using high-throughput technologies. Results: We discovered a widespread epigenetic footprint of HB that includes hyperediting of the tumor suppressor BLCAP concomitant with a genome-wide dysregulation of RNA editing and the overexpression of mainly non-coding genes of the oncogenic 14q32 DLK1-DIO3 locus. By unsupervised analysis, we identified 2 epigenomic clusters (Epi-CA, Epi-CB) with distinct degrees of DNA hypomethylation and CpG island hypermethylation that are associated with the C1/C2/C2B transcriptomic subtypes. Based on these findings, we defined the first molecular risk stratification of HB (MRS-HB), which encompasses 3 main prognostic categories and improves the current clinical risk stratification approach. The MRS-3 category (28%), defined by strong 14q32 locus expression and Epi-CB methylation features, was characterized by CTNNB1 and NFE2L2 mutations, a progenitor-like phenotype and clinical aggressiveness. Finally, we identified choline kinase alpha as a promising therapeutic target for intermediate and high-risk HBs, as its inhibition in HB cell lines and patient-derived xenografts strongly abrogated tumor growth. Conclusions: These findings provide a detailed insight into the molecular features of HB and could be used to improve current clinical stratification approaches and to develop treatments for patients with HB. Lay summary: Hepatoblastoma is a rare childhood liver cancer that has been understudied. We have used cutting-edge technologies to expand our molecular knowledge of this cancer. Our biological findings can be used to improve clinical management and pave the way for the development of novel therapies for this cancer.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Joining European Scientific Forces to Face Pandemics

  • Vasconcelos, M. Helena
  • Alcaro, Stefano
  • Arechavala-Gameza, Virginia
  • Baumbach, Jan
  • Borges, Fernanda
  • Brevini, Tiziana A. L.
  • De Las Rivas, Javier
  • Devaux, Yvan
  • Hozak, Pavel
  • Keinänen-Toivola, Minna M.
  • Lattanzi, Giovanna
  • Mohr, Thomas
  • Murovska, Modra
  • Prusty, Bhupesh K.
  • Quinlan, Roy A.
  • Pérez-Sala, Dolores
  • Scheibenbogen, Carmen
  • Schmidt, Harald H.H.W.
  • Silveira, Isabel
  • Tieri, Paolo
  • Tolios, Alexander
  • Riganti, Chiara
Despite the international guidelines on the containment of the coronavirus disease 2019 (COVID-19) pandemic, the European scientific community was not sufficiently prepared to coordinate scientific efforts. To improve preparedness for future pandemics, we have initiated a network of nine European-funded Cooperation in Science and Technology (COST) Actions that can help facilitate inter-, multi-, and trans-disciplinary communication and collaboration., M.H.V. has grants from FEDER (Fundo Europeu de Desenvolvimento Regional) through COMPETE 2020 and from FCT (Foundation for Science and Technology; POCI-01-0145-FEDER-030457 ; POCI-01-0145-FEDER-016390 : CANCEL STEM). V.A-G. holds a Miguel Servet Fellowship from the ISCIII (CPII17/00004), part-funded by ERDF/FEDER , and acknowledges funding from Ikerbasque (Basque Foundation for Science). T.B. has grants from Carraresi Foundation , EU Horizon 2020 research and innovation programme No 828835 FetOpen and MIND Food’s HUB-Regione Lombardia. J.D.L.R. acknowledges funding from ISCIII (project PI18/00591 ) cofounded by the EU FEDER funds. D.P-S. has grants RTI2018-097624-B-I00 ( AEI, MCI, Spain, and ERDF ), RD16/0006/0021 ( ISCIII, Spain, and ERDF ), and CSIC PTI Global Health ( PIE 202020E223/CSIC-COV19-100 ). H.H.H.W.S. has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 777111 (REPO-TRIAL). I.S. acknowledges funding from FCT (Fundação para a Ciência e Tecnologia), Portugal. C.R. is supported by AIRC (Italian Association for Cancer Research; IG21408 ). C.R. has funding from PharmaMar . Y.D. acknowledges funding from the National Research Fund (grants C14/BM/8225223 , C17/BM/11613033 , and COVID-19/2020-1/14719577/miRCOVID ), the Ministry of Higher Education and Research, and the Heart Foundation – Daniel Wagner of Luxembourg. P.T. acknowledges the support of H2020 project iPC “individualized Paediatric Cure” ( 826121 )., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Deep learning in systems medicine

  • Wang, Haiying
  • Pujos-Guillot, Estelle
  • Comte, Blandine
  • Miranda, Joao Luis de
  • Spiwok, Vojtech
  • Chorbev, Ivan
  • Castiglione, Filippo
  • Tieri, Paolo
  • Watterson, Steven
  • McAllister, Roisin
  • Melo Malaquias, Tiago de
  • Zanin, Massimiliano
  • Rai, Taranjit Singh
  • Zheng, Huiru
Systems medicine (SM) has emerged as a powerful tool for studying the human body at the systems level with the aim of improving our understanding, prevention and treatment of complex diseases. Being able to automatically extract relevant features needed for a given task from high-dimensional, heterogeneous data, deep learning (DL) holds great promise in this endeavour. This review paper addresses the main developments of DL algorithms and a set of general topics where DL is decisive, namely, within the SM landscape. It discusses how DL can be applied to SM with an emphasis on the applications to predictive, preventive and precision medicine. Several key challenges have been highlighted including delivering clinical impact and improving interpretability. We used some prototypical examples to highlight the relevance and significance of the adoption of DL in SM, one of them is involving the creation of a model for personalized Parkinson’s disease. The review offers valuable insights and informs the research in DL and SM., This publication is based upon work from COST Action Open Multiscale Systems Medicine (OpenMultiMed, CA15120), supported by COST (European Cooperation in Science and Technology). COST is funded by the Horizon 2020 Framework Programme of the European Union. HZ and HYW are also supported by the MetaPlat(690998), SenseCare(690862) and STOP(823978) projects funded by H2020 RISE programme. FC and PT acknowledge the support of H2020 project iPC “individualized Paediatric Cure” (826121). Participation of V.S. in OpenMultiMed is supported by the Czech Ministry of Education, Youth and Sports (project LTC18074). JLM. thanks Escola Superior de Tecnologia e Gestão, Instituto Politécnico de Portalegre (ESTG/IPP); and Centro de Recursos Naturais e Ambiente, Instituto Superior Técnico (CERENA/IST) within the support of FCT-Fundação para a Ciência e a Tecnologia through the strategic project FCT-UIDB/04028/2020. MZ acknowledges the Spanish State Research Agency, through the Severo Ochoa and María de Maeztu Program for Centers and Units of Excellence in R&D (MDM-2017-0711) and the funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (851255). The Northern Ireland Centre for Stratified Medicine has been financed by a grant awarded to AJ Bjourson under the European Union Regional Development Fund (ERDF) EU Sustainable Competitiveness Programme for Northern Ireland & the Northern Ireland Public Health Agency (HSC R&D). TSR also acknowledges funding from PHA R&D Division and the Western Health & Social Care., Peer reviewed
UPCommons. Portal del coneixement obert de la UPC
Publicación Artículo científico (JournalArticle)

Artificial intelligence in cancer research: learning at different levels of data granularity

  • Cirillo, Davide|||0000-0003-4982-4716
  • Nuñez Carpintero, Iker|||0000-0002-2637-5236
  • Valencia, Alfonso|||0000-0002-8937-6789
From genome-scale experimental studies to imaging data, behavioral footprints, and longitudinal healthcare records, the convergence of big data in cancer research and the advances in Artificial Intelligence (AI) is paving the way to develop a systems view of cancer. Nevertheless, this biomedical area is largely characterized by the co-existence of big data and small data resources, highlighting the need for a deeper investigation about the crosstalk between different levels of data granularity, including varied sample sizes, labels, data types, and other data descriptors. This review introduces the current challenges, limitations, and solutions of AI in the heterogeneous landscape of data granularity in cancer research. Such a variety of cancer molecular and clinical data calls for advancing the interoperability among AI approaches, with particular emphasis on the synergy between discriminative and generative models that we discuss in this work with several examples of techniques and applications., This work was supported by the European Union's Horizon 2020 research and innovation program under grant agreements 826121 (‘iPC—individualizedPaediatricCure: cloud‐based virtual‐patient models for precision pediatric oncology’)., Peer Reviewed
UPCommons. Portal del coneixement obert de la UPC
Publicación Artículo científico (JournalArticle)

Artificial Intelligence–Aided Precision Medicine for COVID-19: Strategic Areas of Research and Development

  • Santus, Enrico
  • Marino, Nicola
  • Cirillo, Davide|||0000-0003-4982-4716
  • Chersoni, Emmanuele
  • Montagud, Arnau|||0000-0002-7696-1241
  • Santuccione Chadha, Antonella
  • Valencia, Alfonso|||0000-0002-8937-6789
  • Hughes, Kevin
  • Lindvall, Charlotta
Artificial intelligence (AI) technologies can play a key role in preventing, detecting, and monitoring epidemics. In this paper, we provide an overview of the recently published literature on the COVID-19 pandemic in four strategic areas: (1) triage, diagnosis, and risk prediction; (2) drug repurposing and development; (3) pharmacogenomics and vaccines; and (4) mining of the medical literature. We highlight how AI-powered health care can enable public health systems to efficiently handle future outbreaks and improve patient outcomes., We are deeply thankful to the Women’s Brain Project (WBP) (www.womensbrainproject.com), an international organization advocating for women’s brain and mental health through scientific research, debate, and public engagement. The authors would like to thank Maria Teresa Ferretti and Shahnaz Radjy for the helpful comments. DC, AM, and AV have received funding from the European Commission’s Horizon 2020 Program H2020-SC1-DTH-2018-1, “iPC-individualizedPaediatricCure” (ref. 826121), and H2020-ICT-2018-2, “INFORE-Interactive Extreme-Scale Analytics and Forecasting” (ref. 825070)., Peer Reviewed
UPCommons. Portal del coneixement obert de la UPC
Publicación Artículo científico (JournalArticle)

The multilayer community structure of medulloblastoma

  • Nuñez Carpintero, Iker|||0000-0002-2637-5236
  • Petrizzelli, Marianyela
  • Zinovyev, Andrei
  • Cirillo, Davide|||0000-0003-4982-4716
  • Valencia, Alfonso|||0000-0002-8937-6789
Multilayer networks allow interpreting the molecular basis of diseases, which is particularly challenging in rare diseases where the number of cases is small compared with the size of the associated multi-omics datasets. In this work, we develop a dimensionality reduction methodology to identify the minimal set of genes that characterize disease subgroups based on their persistent association in multilayer network communities. We use this approach to the study of medulloblastoma, a childhood brain tumor, using proteogenomic data. Our approach is able to recapitulate known medulloblastoma subgroups (accuracy >94%) and provide a clear characterization of gene associations, with the downstream implications for diagnosis and therapeutic interventions. We verified the general applicability of our method on an independent medulloblastoma dataset (accuracy >98%). This approach opens the door to a new generation of multilayer network-based methods able to overcome the specific dimensionality limitations of rare disease datasets., This work was supported by the Agence Nationale de la Recherche in the program Investissements d’Avenir (project No. ANR-19-P3IA-0001; PRAIRIE 3IA Institute), the European Commission's Horizon 2020 Program, H2020-SC1-DTH-2018-1, “iPC - individualizedPaediatricCure” (ref. 826121), and the Ministry of Science and Higher Education of the Russian Federation (Project No. 14.Y26.31.0022). The authors would like to thank Anaïs Baudot and Léo Pio-Lopez (Marseille Medical Genetics, Inserm) for advising about multilayer community structure analysis, María Rodríguez Martínez and Matteo Manica (IBM Research, Zurich) for text mining support, and François Serra and Miguel Ponce de León (Barcelona Supercomputing Center) for the insightful discussions.
UPCommons. Portal del coneixement obert de la UPC
Publicación Artículo científico (JournalArticle)

Rare disease research workflow using multilayer networks elucidates the molecular determinants of severity in Congenital Myasthenic Syndromes

  • Nuñez Carpintero, Iker|||0000-0002-2637-5236
  • Rigau, Maria|||0000-0002-6501-7212
  • Bosio, Mattia
  • O’Connor, Emily
  • Spendiff, Sally
  • Capella Gutiérrez, Salvador|||0000-0002-0309-604X
  • Cirillo, Davide|||0000-0003-4982-4716
  • Valencia, Alfonso|||0000-0002-8937-6789
Exploring the molecular basis of disease severity in rare disease scenarios is a challenging task provided the limitations on data availability. Causative genes have been described for Congenital Myasthenic Syndromes (CMS), a group of diverse minority neuromuscular junction (NMJ) disorders; yet a molecular explanation for the phenotypic severity differences remains unclear. Here, we present a workflow to explore the functional relationships between CMS causal genes and altered genes from each patient, based on multilayer network community detection analysis of complementary biomedical information provided by relevant data sources, namely protein-protein interactions, pathways and metabolomics. Our results show that CMS severity can be ascribed to the personalized impairment of extracellular matrix components and postsynaptic modulators of acetylcholine receptor (AChR) clustering. This work showcases how coupling multilayer network analysis with personalized -omics information provides molecular explanations to the varying severity of rare diseases; paving the way for sorting out similar cases in other rare diseases., The authors acknowledge the donors and families, Daniel Rico (Newcastle University) for his contribution in early stages of the project, Anaïs Baudot (Aix Marseille Université and Barcelona Supercomputing Center) for her careful revision of the manuscript, Miguel Vázquez (Barcelona Supercomputing Center) for advising about Rbbt analysis, Jon Sánchez-Valle (Barcelona Supercomputing Center) and Núria Olvera (Barcelona Supercomputing Center and IDIBAPS) for the insightful discussions. The authors also acknowledge the corresponding funding institutions: The NeurOmics and RD-Connect projects have been funded by the European Union’s Seventh Framework Programme for research, technological development and demonstration under grant agreements no 2012-305121 and 2012-305444. I.N.C. was supported by a grant for pre-doctoral contracts for the training of doctors (Project ID: SEV-2015-0493-18-2) (Grant ID: PRE2018-083662) from the Spanish Ministry for Science, Innovation and Universities, and the EU project EVENFLOW under Horizon Europe agreement No. 101070430. E.O. was supported by an AFM-Téléthon postdoctoral fellowship for the duration of this work. H.L. receives support from the Canadian Institutes of Health Research (Foundation Grant FDN-167281), the Canadian Institutes of Health Research and Muscular Dystrophy Canada (Network Catalyst Grant for NMD4C), the Canada Foundation for Innovation (CFI-JELF 38412), and the Canada Research Chairs program (Canada Research Chair in Neuromuscular Genomics and Health, 950-232279). V.G. was a research fellow of the Alexander von Humboldt Foundation. D.C. was supported by the European Commission’s Horizon 2020 Program, H2020-SC1-DTH-2018- 1, iPC - individualizedPaediatricCure (ref. 826121)., Peer Reviewed, "Article signat per 18 autors/es: Iker Núñez-Carpintero, Maria Rigau, Mattia Bosio, Emily O’Connor, Sally Spendiff, Yoshiteru Azuma, Ana Topf, Rachel Thompson, Peter A. C. ’t Hoen, Teodora Chamova, Ivailo Tournev, Velina Guergueltcheva, Steven Laurie, Sergi Beltran, Salvador Capella-Gutiérrez, Davide Cirillo, Hanns Lochmüller & Alfonso Valencia "
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Rare disease research workflow using multilayer networks elucidates the molecular determinants of severity in Congenital Myasthenic Syndromes

  • Nuñez Carpintero, Iker
  • Rigau, Maria
  • Bosio, Mattia
  • O’Connor, Emily
  • Spendiff, Sally
  • Capella Gutiérrez, Salvador
  • Cirillo, Davide
  • Valencia, Alfonso
Exploring the molecular basis of disease severity in rare disease scenarios is a challenging task provided the limitations on data availability. Causative genes have been described for Congenital Myasthenic Syndromes (CMS), a group of diverse minority neuromuscular junction (NMJ) disorders; yet a molecular explanation for the phenotypic severity differences remains unclear. Here, we present a workflow to explore the functional relationships between CMS causal genes and altered genes from each patient, based on multilayer network community detection analysis of complementary biomedical information provided by relevant data sources, namely protein-protein interactions, pathways and metabolomics. Our results show that CMS severity can be ascribed to the personalized impairment of extracellular matrix components and postsynaptic modulators of acetylcholine receptor (AChR) clustering. This work showcases how coupling multilayer network analysis with personalized -omics information provides molecular explanations to the varying severity of rare diseases; paving the way for sorting out similar cases in other rare diseases., The authors acknowledge the donors and families, Daniel Rico (Newcastle University) for his contribution in early stages of the project, Anaïs Baudot (Aix Marseille Université and Barcelona Supercomputing Center) for her careful revision of the manuscript, Miguel Vázquez (Barcelona Supercomputing Center) for advising about Rbbt analysis, Jon Sánchez-Valle (Barcelona Supercomputing Center) and Núria Olvera (Barcelona Supercomputing Center and IDIBAPS) for the insightful discussions. The authors also acknowledge the corresponding funding institutions: The NeurOmics and RD-Connect projects have been funded by the European Union’s Seventh Framework Programme for research, technological development and demonstration under grant agreements no 2012-305121 and 2012-305444. I.N.C. was supported by a grant for pre-doctoral contracts for the training of doctors (Project ID: SEV-2015-0493-18-2) (Grant ID: PRE2018-083662) from the Spanish Ministry for Science, Innovation and Universities, and the EU project EVENFLOW under Horizon Europe agreement No. 101070430. E.O. was supported by an AFM-Téléthon postdoctoral fellowship for the duration of this work. H.L. receives support from the Canadian Institutes of Health Research (Foundation Grant FDN-167281), the Canadian Institutes of Health Research and Muscular Dystrophy Canada (Network Catalyst Grant for NMD4C), the Canada Foundation for Innovation (CFI-JELF 38412), and the Canada Research Chairs program (Canada Research Chair in Neuromuscular Genomics and Health, 950-232279). V.G. was a research fellow of the Alexander von Humboldt Foundation. D.C. was supported by the European Commission’s Horizon 2020 Program, H2020-SC1-DTH-2018- 1, iPC - individualizedPaediatricCure (ref. 826121)., Peer Reviewed, "Article signat per 18 autors/es: Iker Núñez-Carpintero, Maria Rigau, Mattia Bosio, Emily O’Connor, Sally Spendiff, Yoshiteru Azuma, Ana Topf, Rachel Thompson, Peter A. C. ’t Hoen, Teodora Chamova, Ivailo Tournev, Velina Guergueltcheva, Steven Laurie, Sergi Beltran, Salvador Capella-Gutiérrez, Davide Cirillo, Hanns Lochmüller & Alfonso Valencia ", Postprint (published version)
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Epigenetic footprint enables molecular risk stratification of hepatoblastoma with clinical implications

  • Carrillo Reixach, Juan
  • Torrens, Laura
  • Simon Coma, Marina
  • Royo, Laura
  • Domingo Sàbat, Montserrat
  • Abril Fornaguera, Jordi
  • Akers, Nicholas
  • Sala, Margarita
  • Ragull Tisner, Sònia
  • Arnal, Magdalena
  • Villalmanzo, Núria
  • Cairo, Stefano
  • Villanueva Garatachea, Alberto
  • Kappler, Roland
  • Garrido, Marta
  • Guerra, Laura
  • Sabado, Constantino
  • Guillén, Gabriela
  • Mallo, Mar
  • Piñeyro, David
  • Vázquez Vitali, María
  • Kuchuk, Olga
  • Mateos, María Elena
  • Ramírez, Gema
  • López Santamaría, Manuel
  • Mozo, Yasmina
  • Soriano, Aroa
  • Grotzer, Michael
  • Branchereau, Sophie
  • García de Andoin, Nagore
  • López Ibor, Blanca
  • López Almaraz, Ricardo
  • Salinas, José Antonio
  • Torres, Bárbara
  • Hernández, Francisco
  • Uriz, José Javier
  • Fabre, Monique
  • Blanco, Julià
  • Paris, Claudia
  • Bajciová, Viera
  • Laureys, Geneviève
  • Masnou, Helena
  • Clos, Ariadna
  • Belendez, Cristina
  • Guettier, Catherine
  • Sumoy, Lauro
  • Planas, Ramón
  • Jordà Ramos, Mireia
  • Nonell, Lara
  • Czauderna, Piotr
  • Morland, Bruce
  • Sia, Daniela
  • Losic, Bojan
  • Buendia, Marie Annick
  • Sarrias Fornés, Maria Rosa
  • Llovet i Bayer, Josep Maria
  • Armengol, Carolina
Background & Aims: Hepatoblastoma (HB) is a rare disease. Nevertheless, it is the predominant pediatric liver cancer, with limited therapeutic options for patients with aggressive tumors. Herein, we aimed to uncover the mechanisms of HB pathobiology and to identify new biomarkers and therapeutic targets in a move towards precision medicine for patients with advanced HB. Methods: We performed a comprehensive genomic, transcriptomic and epigenomic characterization of 159 clinically annotated samples from 113 patients with HB, using high-throughput technologies. Results: We discovered a widespread epigenetic footprint of HB that includes hyperediting of the tumor suppressor BLCAP concomitant with a genome-wide dysregulation of RNA editing and the overexpression of mainly non-coding genes of the oncogenic 14q32 DLK1-DIO3 locus. By unsupervised analysis, we identified 2 epigenomic clusters (Epi-CA, Epi-CB) with distinct degrees of DNA hypomethylation and CpG island hypermethylation that are associated with the C1/C2/C2B transcriptomic subtypes. Based on these findings, we defined the first molecular risk stratification of HB (MRS-HB), which encompasses 3 main prognostic categories and improves the current clinical risk stratification approach. The MRS-3 category (28%), defined by strong 14q32 locus expression and Epi-CB methylation features, was characterized by CTNNB1 and NFE2L2 mutations, a progenitor-like phenotype and clinical aggressiveness. Finally, we identified choline kinase alpha as a promising therapeutic target for intermediate and high-risk HBs, as its inhibition in HB cell lines and patient-derived xenografts strongly abrogated tumor growth. Conclusions: These findings provide a detailed insight into the molecular features of HB and could be used to improve current clinical stratification approaches and to develop treatments for patients with HB. Lay summary: Hepatoblastoma is a rare childhood liver cancer that has been understudied. We have used cutting-edge technologies to expand our molecular knowledge of this cancer. Our biological findings can be used to improve clinical management and pave the way for the development of novel therapies for this cancer.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

The multilayer community structure of medulloblastoma

  • Nuñez Carpintero, Iker
  • Petrizzelli, Marianyela
  • Zinovyev, Andrei
  • Cirillo, Davide
  • Valencia, Alfonso
Multilayer networks allow interpreting the molecular basis of diseases, which is particularly challenging in rare diseases where the number of cases is small compared with the size of the associated multi-omics datasets. In this work, we develop a dimensionality reduction methodology to identify the minimal set of genes that characterize disease subgroups based on their persistent association in multilayer network communities. We use this approach to the study of medulloblastoma, a childhood brain tumor, using proteogenomic data. Our approach is able to recapitulate known medulloblastoma subgroups (accuracy >94%) and provide a clear characterization of gene associations, with the downstream implications for diagnosis and therapeutic interventions. We verified the general applicability of our method on an independent medulloblastoma dataset (accuracy >98%). This approach opens the door to a new generation of multilayer network-based methods able to overcome the specific dimensionality limitations of rare disease datasets., This work was supported by the Agence Nationale de la Recherche in the program Investissements d’Avenir (project No. ANR-19-P3IA-0001; PRAIRIE 3IA Institute), the European Commission's Horizon 2020 Program, H2020-SC1-DTH-2018-1, “iPC - individualizedPaediatricCure” (ref. 826121), and the Ministry of Science and Higher Education of the Russian Federation (Project No. 14.Y26.31.0022). The authors would like to thank Anaïs Baudot and Léo Pio-Lopez (Marseille Medical Genetics, Inserm) for advising about multilayer community structure analysis, María Rodríguez Martínez and Matteo Manica (IBM Research, Zurich) for text mining support, and François Serra and Miguel Ponce de León (Barcelona Supercomputing Center) for the insightful discussions., Postprint (published version)
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

DECONbench: a benchmarking platform dedicated to deconvolution methods for tumor heterogeneity quantification

  • Decamps, Clémentine
  • Arnaud, Alexis
  • Petitprez, Florent
  • Ayadi, Mira
  • Baurès, Aurélia
  • Armenoult, Lucile
  • Escalera Guerrero, Sergio
  • Guyon, Isabelle
  • Nicolle, Rémy
  • Tomasini, Richard
  • Reyniès, Aurélien de
  • Cros, Jérôme
  • Blum, Yuna
  • Richard, Magali
Quantifcation of tumor heterogeneity is essential to better understand cancer progression and to adapt therapeutic treatments to patient specifcities. Bioinformatic tools to assess the diferent cell populations from single-omic datasets as bulk transcriptome or methylome samples have been recently developed, including reference-based and reference-free methods. Improved methods using multi-omic datasets are yet to be developed in the future and the community would need systematic tools to perform a comparative evaluation of these algorithms on controlled data.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

MacroH2As regulate enhancer-promoter contacts affecting enhancer activity and sensitivity to inflammatory cytokines

  • Corujo, David
  • Malinverni, Roberto
  • Carrillo-Reixach, Juan
  • Meers, Oliver
  • Garcia-Jaraquemada, Arce
  • Le Pannérer, Marguerite-Marie, 1990-
  • Valero, Vanesa
  • Pérez, Ainhoa
  • Del Río-Álvarez, Álvaro
  • Royo, Laura
  • Pérez-González, Beatriz
  • Raurell Vila, Helena
  • Acemel, Rafael D.
  • Santos-Pereira, José M.
  • Gómez Skarmeta, José Luis
  • Pasquali, Lorenzo
  • Manyé, Josep
  • Armengol, Carolina
  • Buschbeck, Marcus
MacroH2A histone variants have a function in gene regulation that is poorly understood at the molecular level. We report that macroH2A1.2 and macroH2A2 modulate the transcriptional ground state of cancer cells and how they respond to inflammatory cytokines. Removal of macroH2A1.2 and macroH2A2 in hepatoblastoma cells affects the contact frequency of promoters and distal enhancers coinciding with changes in enhancer activity or preceding them in response to the cytokine tumor necrosis factor alpha. Although macroH2As regulate genes in both directions, they globally facilitate the nuclear factor κB (NF-κB)-mediated response. In contrast, macroH2As suppress the response to the pro-inflammatory cytokine interferon gamma. MacroH2A2 has a stronger contribution to gene repression than macroH2A1.2. Taken together, our results suggest that macroH2As have a role in regulating the response of cancer cells to inflammatory signals on the level of chromatin structure. This is likely relevant for the interaction of cancer cells with immune cells of their microenvironment., This research project was supported by the national grants RTI2018-094005-B-I00 and BFU2015-66559-P from FEDER / Ministerio de Ciencia e Innovación - Agencia Estatal de Investigación (to M.B.); PI09/00751 , PI10/02082 , and PI13/02340 from the Instituto de Salud Carlos III (to C.A.); the MECD fellowship FPU14/06542 (to D.C.); AGAUR 2019 FI_B01024 and 2022 FI_B00528 fellowships (to J.C.-R. and A.D.R.-A., respectively); and predoctoral fellowships BES-2016-077251 (to M.-M.L.P.) and PRE2019-088529 (to O.M.). Research in the M.B. lab is further supported by the following grants: the Marie Skłodowska Curie Training network “ INTERCEPT-MDS ” H2020-MSCA-ITN-2020-953407 (to M.B.); MINECO-ISCIII PIE16/00011 (to M.B.); the Deutsche José Carreras Leukämie Stiftung DJCLS 14R/2018 (to M.B.); AGAUR 2017-SGR-305 (to M.B.); and Fundació La Marató de TV3 257/C/2019 (to M.B.). C.A.’s research has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement nos. 668596 ( ChiLTERN ) and 826121 ( iPC ) as well as from CIBERehd ( CB06/04/0033 ) and AGAUR ( 2017-SGR-490 ). C.A. was supported by Ramón y Cajal ( RYC-2010-07249 ) of the Ministry of Science and Innovation of Spain. Research at the IJC is supported by the “ La Caixa” Foundation , the Fundació Internacional Josep Carreras , Celgene Spain , and the CERCA Programme / Generalitat de Catalunya.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Analyzing sex imbalance in EGA and dbGaP biological databases: Recommendations for better practices

  • Ruiz-Serra, Victoria
  • Buslón, Nataly
  • Philippe, Olivier
  • Saby, Diego
  • Morales, María
  • Pontes, Camila
  • Muñoz Andirkó, Alejandro
  • Holliday, Gemma L.
  • Jene, Aina
  • Moldes, Mauricio
  • Rambla de Argila, Jordi
  • Valencia, Alfonso
  • Rementeria, María José
  • Cortés, Atia
  • Cirillo, Davide
Precision medicine aims at tailoring treatments to individual patient's characteristics. In this regard, recognizing the significance of sex and gender becomes indispensable for meeting the distinct healthcare needs of diverse populations. To this end, continuing a trend of improving data quality observed since 2014, the European Genome-phenome Archive (EGA) established a policy in 2018 that mandates data providers to declare the sex of donor samples, aiming to enhance data accuracy and prevent imbalance in sex classification. We analyzed sex classification imbalance in human data from EGA and the U.S. counterpart, the database of genotypes and phenotypes (dbGaP). Our findings show a significant decrease in samples classified as unknown in EGA, potentially promoting better sex reporting during data collection. Based on our findings, we raise awareness of sample imbalance problems and provide a list of recommendations for enhancing biomedical research practices., The work has been supported by Bioinfo4Women through the project Excelencia Severo Ochoa (ref. CEX2021-001148-S) and the European Commission's Horizon 2020 Program, H2020-SC1-DTH-2018-2020, “iPC - individualizedPaediatricCure” (GA 826121). This work was conceptualized and prototyped during the BioHackathon Europe, organized and funded by the ELIXIR Hub in November 2021 in Barcelona. We thank the organizers for an opportunity to participate in such a productive and collaborative event. The authors would like to acknowledge the initiative Bioinfo4Women, Laura Rodríguez Navas (Spanish National Bioinformatics Institute, INB/ELIXIR-ES and Barcelona Supercomputing Center, BSC), Eva Alloza (Spanish National Bioinformatics Institute, INB/ELIXIR-ES and Barcelona Supercomputing Center, BSC), Francisco Garcia-Garcia (Prince Felipe Research Center, CIPF), Babita Singh (Center for Genomic Regulation, CRG), Ben Busby (DNANexus), and Michael Feolo (dbGaP) and the NCBI dbGaP support team. C.P. is supported by the fellowship Juan de La Cierva - Formación from the Spanish Ministry of Education and Science (ref. FJC2021-046655-I).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Artificial Intelligence–Aided Precision Medicine for COVID-19: Strategic Areas of Research and Development

  • Santus, Enrico
  • Marino, Nicola
  • Cirillo, Davide
  • Chersoni, Emmanuele
  • Montagud, Arnau
  • Santuccione Chadha, Antonella
  • Valencia, Alfonso
  • Hughes, Kevin
  • Lindvall, Charlotta
Artificial intelligence (AI) technologies can play a key role in preventing, detecting, and monitoring epidemics. In this paper, we provide an overview of the recently published literature on the COVID-19 pandemic in four strategic areas: (1) triage, diagnosis, and risk prediction; (2) drug repurposing and development; (3) pharmacogenomics and vaccines; and (4) mining of the medical literature. We highlight how AI-powered health care can enable public health systems to efficiently handle future outbreaks and improve patient outcomes., We are deeply thankful to the Women’s Brain Project (WBP) (www.womensbrainproject.com), an international organization advocating for women’s brain and mental health through scientific research, debate, and public engagement. The authors would like to thank Maria Teresa Ferretti and Shahnaz Radjy for the helpful comments. DC, AM, and AV have received funding from the European Commission’s Horizon 2020 Program H2020-SC1-DTH-2018-1, “iPC-individualizedPaediatricCure” (ref. 826121), and H2020-ICT-2018-2, “INFORE-Interactive Extreme-Scale Analytics and Forecasting” (ref. 825070)., Peer Reviewed, Postprint (published version)
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Artificial intelligence in cancer research: learning at different levels of data granularity

  • Cirillo, Davide
  • Nuñez Carpintero, Iker
  • Valencia, Alfonso
From genome-scale experimental studies to imaging data, behavioral footprints, and longitudinal healthcare records, the convergence of big data in cancer research and the advances in Artificial Intelligence (AI) is paving the way to develop a systems view of cancer. Nevertheless, this biomedical area is largely characterized by the co-existence of big data and small data resources, highlighting the need for a deeper investigation about the crosstalk between different levels of data granularity, including varied sample sizes, labels, data types, and other data descriptors. This review introduces the current challenges, limitations, and solutions of AI in the heterogeneous landscape of data granularity in cancer research. Such a variety of cancer molecular and clinical data calls for advancing the interoperability among AI approaches, with particular emphasis on the synergy between discriminative and generative models that we discuss in this work with several examples of techniques and applications., This work was supported by the European Union's Horizon 2020 research and innovation program under grant agreements 826121 (‘iPC—individualizedPaediatricCure: cloud‐based virtual‐patient models for precision pediatric oncology’)., Peer Reviewed, Postprint (published version)
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Epigenetic footprint enables molecular risk stratification of hepatoblastoma with clinical implications

  • Carrillo-Reixach, Juan|||0000-0002-8538-8264
  • Torrens, Laura
  • Simón-Coma, Marina
  • Royo, Laura|||0000-0001-5770-2001
  • Domingo-Sàbat, Montse|||0000-0001-6687-3259
  • Abril-Fornaguera, Jordi|||0000-0002-5871-4052
  • Akers, Nicholas
  • Sala Llinas, Margarita|||0000-0003-4879-1780
  • Ragull, Sonia
  • Arnal, Magdalena|||0000-0001-8647-9232
  • Villalmanzo, Núria
  • Cairo, Stefano
  • Villanueva, Alejandro|||0000-0001-5164-0006
  • Kappler, Roland
  • Garrido-Pontnou, Marta|||0000-0002-7762-7085
  • Guerra Pastrian, Laura|||0000-0002-8478-8522
  • Sábado, Constantino|||0000-0003-3956-5466
  • Guillén, Gabriela|||0000-0001-5632-2672
  • Mallo, Maria del Mar|||0000-0001-7741-498X
  • Piñeyro, David|||0000-0001-5633-3339
  • Vázquez-Vitali, María
  • Kuchuk, Olga
  • Mateos, María Elena
  • Ramírez, Gema
  • López Santamaría, Manuel
  • Mozo, Yasmina
  • Soriano, Aroa|||0000-0001-9659-1471
  • Grotzer, Michael
  • Branchereau, Sophie
  • García de Andoin, Nagore
  • López-Ibor, Blanca
  • López-Almaraz, Ricardo
  • Salinas, José Antonio
  • Torres, Bárbara
  • Hernández, Francisco
  • Uriz, José Javier
  • Fabre, Monique
  • Blanco, Julià|||0000-0002-2225-0217
  • Paris, Claudia
  • Bajčiová, Viera
  • Laureys, Geneviève
  • Masnou, Helena|||0000-0003-0632-1393
  • Clos, Ariadna|||0000-0002-6414-2097
  • Beléndez, Cristina|||0000-0002-6019-6557
  • Guettier, Catherine
  • Sumoy, Lauro|||0000-0003-0005-4618
  • Planas, Ramón
  • Jordà, Mireia|||0000-0003-3709-1850
  • Nonell, Lara|||0000-0002-8538-8213
  • Czauderna, Piotr
  • Morland, Bruce
  • Sia, Daniela|||0000-0002-9000-611X
  • Losic, Bojan
  • Buendia, Marie Annick
  • Sarrias, Maria-Rosa|||0000-0001-6929-8069
  • Llovet, Josep M.|||0000-0003-0547-2667
  • Armengol, Carolina|||0000-0002-4690-4027
Background & Aims: Hepatoblastoma (HB) is a rare disease. Nevertheless, it is the predominant pediatric liver cancer, with limited therapeutic options for patients with aggressive tumors. Herein, we aimed to uncover the mechanisms of HB pathobiology and to identify new biomarkers and therapeutic targets in a move towards precision medicine for patients with advanced HB. Methods: We performed a comprehensive genomic, transcriptomic and epigenomic characterization of 159 clinically annotated samples from 113 patients with HB, using high-throughput technologies. Results: We discovered a widespread epigenetic footprint of HB that includes hyperediting of the tumor suppressor BLCAP concomitant with a genome-wide dysregulation of RNA editing and the overexpression of mainly non-coding genes of the oncogenic 14q32 DLK1-DIO3 locus. By unsupervised analysis, we identified 2 epigenomic clusters (Epi-CA, Epi-CB) with distinct degrees of DNA hypomethylation and CpG island hypermethylation that are associated with the C1/C2/C2B transcriptomic subtypes. Based on these findings, we defined the first molecular risk stratification of HB (MRS-HB), which encompasses 3 main prognostic categories and improves the current clinical risk stratification approach. The MRS-3 category (28%), defined by strong 14q32 locus expression and Epi-CB methylation features, was characterized by CTNNB1 and NFE2L2 mutations, a progenitor-like phenotype and clinical aggressiveness. Finally, we identified choline kinase alpha as a promising therapeutic target for intermediate and high-risk HBs, as its inhibition in HB cell lines and patient-derived xenografts strongly abrogated tumor growth. Conclusions: These findings provide a detailed insight into the molecular features of HB and could be used to improve current clinical stratification approaches and to develop treatments for patients with HB. Lay summary: Hepatoblastoma is a rare childhood liver cancer that has been understudied. We have used cutting-edge technologies to expand our molecular knowledge of this cancer. Our biological findings can be used to improve clinical management and pave the way for the development of novel therapies for this cancer.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

MacroH2As regulate enhancer-promoter contacts affecting enhancer activity and sensitivity to inflammatory cytokines

  • Corujo, David|||0000-0001-7930-0935
  • Malinverni, Roberto|||0000-0002-0113-3417
  • Carrillo-Reixach, Juan|||0000-0002-8538-8264
  • Meers, Oliver|||0000-0001-9532-7767
  • Garcia-Jaraquemada, Arce|||0000-0001-6603-2003
  • Le Pannérer, Marguerite Marie|||0000-0002-5779-8805
  • Valero, Vanesa
  • Pérez, Ainoha
  • Del Río-Álvarez, Álvaro|||0000-0003-2338-0782
  • Royo, Laura|||0000-0001-5770-2001
  • Pérez-González, Beatriz|||0000-0001-9849-5176
  • Raurell Vila, Helena|||0000-0003-1196-836X
  • Acemel, Rafael D.|||0000-0003-4120-0140
  • Santos-Pereira, José M.|||0000-0003-3949-0644
  • Garrido-Pontnou, Marta|||0000-0002-7762-7085
  • Gómez-Skarmeta, José Luís|||0000-0001-5125-4332
  • Pasquali, Lorenzo|||0000-0003-2423-1826
  • Manyé, Josep|||0000-0002-3121-8016
  • Armengol, Carolina|||0000-0002-4690-4027
  • Buschbeck, Marcus|||0000-0002-3218-4567
MacroH2A histone variants have a function in gene regulation that is poorly understood at the molecular level. We report that macroH2A1.2 and macroH2A2 modulate the transcriptional ground state of cancer cells and how they respond to inflammatory cytokines. Removal of macroH2A1.2 and macroH2A2 in hepatoblastoma cells affects the contact frequency of promoters and distal enhancers coinciding with changes in enhancer activity or preceding them in response to the cytokine tumor necrosis factor alpha. Although macroH2As regulate genes in both directions, they globally facilitate the nuclear factor κB (NF-κB)-mediated response. In contrast, macroH2As suppress the response to the pro-inflammatory cytokine interferon gamma. MacroH2A2 has a stronger contribution to gene repression than macroH2A1.2. Taken together, our results suggest that macroH2As have a role in regulating the response of cancer cells to inflammatory signals on the level of chromatin structure. This is likely relevant for the interaction of cancer cells with immune cells of their microenvironment.